Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Francis KE, Simon S, Gebski V, Joly F, Ledermann JA, Penson RT, Oza AM, Korach J, Lainez N, Cecere SC, Tasca G, Gropp-Meier M, Fujiwara K, Lowe ES, Friedlander M, Pujade-Lauraine E, Lee CK. Francis KE, et al. Among authors: gebski v. Gynecol Oncol. 2024 Nov 12;192:50-55. doi: 10.1016/j.ygyno.2024.11.004. Online ahead of print. Gynecol Oncol. 2024. PMID: 39536691 Free article.
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, Bradshaw N, Lee YC, Diamante K, Fyles AW, Small W Jr, Gaffney DK, Khaw P, Brooks S, Thompson JS, Huh WK, Mathews CA, Buck M, Suder A, Lad TE, Barani IJ, Holschneider CH, Van Dyk S, Quinn M, Rischin D, Monk BJ, Stockler MR. Mileshkin LR, et al. Among authors: gebski v. Lancet Oncol. 2023 May;24(5):468-482. doi: 10.1016/S1470-2045(23)00147-X. Epub 2023 Apr 17. Lancet Oncol. 2023. PMID: 37080223 Free PMC article. Clinical Trial.
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.
Barbour AP, Walpole ET, Mai GT, Barnes EH, Watson DI, Ackland SP, Martin JM, Burge M, Finch R, Karapetis CS, Shannon J, Nott LM, Varma S, Marx G, Falk GL, Gebski V, Oostendorp M, Wilson K, Thomas J, Lampe G, Zalcberg JR, Simes J, Smithers BM; DOCTOR investigators. Barbour AP, et al. Among authors: gebski v. Ann Oncol. 2020 Feb;31(2):236-245. doi: 10.1016/j.annonc.2019.10.019. Epub 2019 Dec 23. Ann Oncol. 2020. PMID: 31959340 Free article. Clinical Trial.
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.
Bonazzi VF, Aoude LG, Brosda S, Bradford JJ, Lonie JM, Loffler KA, Gartside MG, Patel K, Mukhopadhyay P, Keane C, Gebski V, Kench JG, Goldstein D, Waddell N, Barbour AP; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. Bonazzi VF, et al. Among authors: gebski v. Asia Pac J Clin Oncol. 2023 Jul 6. doi: 10.1111/ajco.13993. Online ahead of print. Asia Pac J Clin Oncol. 2023. PMID: 37415393
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
Mann GB, Skandarajah AR, Zdenkowski N, Hughes J, Park A, Petrie D, Saxby K, Grimmond SM, Murugasu A, Spillane AJ, Chua BH, Badger H, Braggett H, Gebski V, Mou A, Collins JP, Rose AK. Mann GB, et al. Among authors: gebski v. Lancet. 2024 Jan 20;403(10423):261-270. doi: 10.1016/S0140-6736(23)02476-5. Epub 2023 Dec 5. Lancet. 2024. PMID: 38065194 Clinical Trial.
10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection.
Campbell I, Wetzig N, Ung O, Espinoza D, Farshid G, Collins J, Kollias J, Gebski V, Mister R, Simes RJ, Stockler MR, Gill G. Campbell I, et al. Among authors: gebski v. Breast. 2023 Aug;70:70-75. doi: 10.1016/j.breast.2023.06.009. Epub 2023 Jun 23. Breast. 2023. PMID: 37393644 Free PMC article. Clinical Trial.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
Lam LL, Pavlakis N, Shitara K, Sjoquist KM, Martin AJ, Yip S, Kang YK, Bang YJ, Chen LT, Moehler M, Bekaii-Saab T, Alcindor T, O'Callaghan CJ, Tebbutt NC, Hague W, Chan H, Rha SY, Lee KW, Gebski V, Jaworski A, Zalcberg J, Price T, Simes J, Goldstein D. Lam LL, et al. Among authors: gebski v. BMC Cancer. 2023 Feb 22;23(1):180. doi: 10.1186/s12885-023-10642-7. BMC Cancer. 2023. PMID: 36814222 Free PMC article. Clinical Trial.
Predicting Type 2 Diabetes and Testosterone Effects in high-risk Australian men: Development and external validation of a 2 year risk model.
Robledo KP, Marschner IC, Grossmann M, Handelsman DJ, Yeap BB, Allan CA, Foote C, Inder WJ, Stuckey BGA, Jesudason D, Bracken K, Keech AC, Jenkins AJ, Gebski V, Jardine M, Wittert G. Robledo KP, et al. Among authors: gebski v. Eur J Endocrinol. 2024 Dec 25:lvae166. doi: 10.1093/ejendo/lvae166. Online ahead of print. Eur J Endocrinol. 2024. PMID: 39720906
The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database.
Sengupta C, Nguyen DT, Li Y, Hewson E, Ball H, O'Brien R, Booth J, Kipritidis J, Eade T, Kneebone A, Hruby G, Bromley R, Greer P, Martin J, Hunter P, Wilton L, Moodie T, Hayden A, Turner S, Hardcastle N, Siva S, Tai KH, Arumugam S, Sidhom M, Poulsen P, Gebski V, Moore A, Keall P. Sengupta C, et al. Among authors: gebski v. Med Phys. 2024 Nov 23. doi: 10.1002/mp.17529. Online ahead of print. Med Phys. 2024. PMID: 39579383
Preoperative Chemoradiotherapy for Resectable Gastric Cancer.
Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, O'Connell RL, Zalcberg J, Boussioutas A, Findlay M, Willis D, Moore A, Murray WK, Lordick F, O'Callaghan C, Swallow C, Darling G, Miller D, Strickland A, Liberman M, Mineur L, Simes J; Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group. Leong T, et al. Among authors: gebski v. N Engl J Med. 2024 Nov 14;391(19):1810-1821. doi: 10.1056/NEJMoa2405195. Epub 2024 Sep 14. N Engl J Med. 2024. PMID: 39282905 Clinical Trial.
427 results